

FIGURES

FIGURE 1. Selected novel Ig Binding proteins.

SEQ ID	remarks	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58
4	cs26 8I	I	A	A	Q	H	D	K	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
6	cs26 8F	I	A	A	Q	H	D	K	F	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
7	cs26 8Y	I	A	A	Q	H	D	K	Y	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
8	cs26 8W	I	A	A	Q	H	D	K	W	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
9	cs26 8L	I	A	A	Q	H	D	K	L	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
10	cs26 6I	I	A	A	Q	H	I	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
11	cs26 6Y	I	A	A	Q	H	Y	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
12	cs26 6W	I	A	A	Q	H	W	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
14	cs26 6L	I	A	A	Q	H	L	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	C	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
15	cs26 4I	I	A	A	I	H	D	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
16	cs26 4F	I	A	A	F	H	D	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
17	cs26 4W	I	A	A	W	H	D	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
18	cs26 4L	I	A	A	L	H	D	K	D	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
20	cs26 8I 14H	I	A	A	Q	H	D	K	I	Q	Q	A	A	F	H	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	A	E	A	K	K	L	N	D	A	Q	A	P	K
25	cs27 8I	I	A	A	K	F	D	E	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	V	L	G	E	A	Q	K	L	N	D	S	Q	A	P	K
26	cs27 8I 14H	I	A	A	K	F	D	E	I	Q	Q	A	A	F	H	E	I	L	H	L	P	N	L	T	E	E	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	V	L	G	E	A	Q	K	L	N	D	S	Q	A	P	K
27	cs27 8I 28H	I	A	A	K	F	D	E	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	E	Q	R	H	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	V	L	G	E	A	Q	K	L	N	D	S	Q	A	P	K
28	cs59 8I	I	D	A	K	F	D	E	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	D	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	A	L	L	A	E	A	K	K	L	N	D	A	Q	A	P	P
29	cs59 8I 14H	I	D	A	K	F	D	E	I	Q	Q	A	A	F	H	E	I	L	H	L	P	N	L	T	E	D	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	A	L	L	A	E	A	K	K	L	N	D	A	Q	A	P	P
30	cs59 8I 28H	I	D	A	K	F	D	E	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	D	Q	R	H	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	A	L	L	A	E	A	K	K	L	N	D	A	Q	A	P	P
31	cs60 8I	I	D	A	K	F	D	E	I	A	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	D	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	A	L	L	A	E	A	K	K	L	N	D	A	Q	A	P	P
32	cs60 8I 14H	I	D	A	K	F	D	E	I	A	Q	A	A	F	H	E	I	L	H	L	P	N	L	T	E	D	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	A	L	L	A	E	A	K	K	L	N	D	A	Q	A	P	P
33	cs60 8I 28H	I	D	A	K	F	D	E	I	A	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	D	Q	R	H	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	A	L	L	A	E	A	K	K	L	N	D	A	Q	A	P	P
34	cs14 8I	I	A	A	K	H	D	K	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	D	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	G	E	A	K	K	L	N	D	A	Q	A	P	P
35	cs14 8I 14H	I	A	A	K	H	D	K	I	Q	Q	A	A	F	H	E	I	L	H	L	P	N	L	T	E	D	Q	R	N	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	G	E	A	K	K	L	N	D	A	Q	A	P	P
36	cs14 8I 28H	I	A	A	K	H	D	K	I	Q	Q	A	A	F	Y	E	I	L	H	L	P	N	L	T	E	D	Q	R	H	A	F	I	Q	S	L	R	D	D	P	S	V	S	L	E	I	L	G	E	A	K	K	L	N	D	A	Q	A	P	P

FIGURE 2. Remaining activity after NaOH incubation (pos. 8 modifications)




FIGURE 3. Remaining activity after NaOH incubation (pos. 4 modifications)




FIGURE 4. Remaining activity after NaOH incubation (pos. 6 modifications)




FIGURE 5. Elution profile of Belimumab from affinity ligand SEQ ID NO: 51 (pH gradient pH 6.0 to 2.0)




Figure 6. DBC10% determination of affinity ligand SEQ ID NO: 51; the antibody eluted completely at pH 4.8.

